| | |
| Insight: Presidency beckons for Jakarta's rags-to-riches governor Saturday, Jun 01, 2013 05:17 PM PDT  By Kanupriya Kapoor and Andrew R.C. Marshall JAKARTA (Reuters) - Joko "Jokowi" Widodo, the governor of Jakarta, might well be the future of Indonesian democracy. Here's why. On a recent afternoon he visited Tambora, a densely populated area of west Jakarta, to inspect the aftermath of a slum fire. Within minutes, the narrow streets were a moshpit of jostling well-wishers. Women embraced him. Men kissed his hand. ... Full Story | Top |
| Glaxo drug shown to delay ovarian cancer relapse Saturday, Jun 01, 2013 09:08 AM PDT By Deena Beasley CHICAGO (Reuters) - A cancer drug sold by GlaxoSmithKline was shown in a clinical trial to extend by several months the length of time ovarian cancer patients lived without their disease worsening. The findings suggest that the oral drug, Votrient, could be used as a "maintenance" therapy for many ovarian cancer patients whose disease had returned after initial surgery and chemotherapy. "This is the first positive clinical trial for a targeted agent in ovarian cancer," said lead study author Dr. ... Full Story | Top |
| Dutch authorities to cull poultry after avian influenza outbreak Saturday, Jun 01, 2013 05:20 AM PDT AMSTERDAM (Reuters) - Health authorities will cull 11,000 chickens at a farm in the Netherlands after an outbreak of a mild form of avian influenza, the Dutch Economic Affairs Ministry said on Saturday. The chickens were believed to have the low pathogenic H7 strain, the ministry said in a statement. They would be culled as a precaution because the strain can mutate into a form that is fatal for poultry. Authorities imposed a one-kilometer safety perimeter around the farm banning transports of poultry, eggs and other farm products. ... Full Story | Top |
| Russia tries to kick habit with anti-smoking law Saturday, Jun 01, 2013 04:42 AM PDT  By Steve Gutterman MOSCOW (Reuters) - Tobacco restrictions came into force in Russia on Saturday which President Vladimir Putin hopes will create a healthier workforce and help reverse a population decline, but they face stiff opposition in a country where four in ten people smoke. The measures, part of a law Putin signed in February, include a ban on smoking at schools and universities, museums, sports facilities, hospitals and on public transport - in many cases places where it is already prohibited. ... Full Story | Top |
| Drug is a first to help patients with melanoma of the eye Saturday, Jun 01, 2013 04:33 AM PDT By Julie Steenhuysen CHICAGO (Reuters) - In his first few weeks as head of the melanoma group at Memorial Sloan-Kettering Cancer Center seven years ago, a young man walked into Dr. Gary Schwartz's office with a rare form of the skin cancer that affects the eye. "It was horrible. He died of metastatic disease. He was only 24. I promised him I would find a way to cure his cancer," recalls the physician-scientist of the patient who helped inspire his quest to find an effective treatment for uveal melanoma, which affects 2,000 to 3,000 patients each year. ... Full Story | Top |
| Bristol drug shrinks melanoma in 31 percent of trial patients Saturday, Jun 01, 2013 04:33 AM PDT By Deena Beasley CHICAGO (Reuters) - An experimental drug from Bristol-Myers Squibb shrank tumors in 31 percent of patients with advanced melanoma, the deadliest form of skin cancer, according to results from an early-stage trial. The drug, nivolumab, is the most advanced in a new class of immunotherapies designed to work by disabling a brake on the immune system's ability to attack cancer cells. An existing immunotherapy drug, Bristol's Yervoy, which works by disrupting a different cell receptor, has been shown to be effective in up to 10 percent of people with advanced melanoma. ... Full Story | Top |
| Amgen melanoma drug improved survival by 21 percent in interim look Saturday, Jun 01, 2013 04:32 AM PDT By Deena Beasley CHICAGO (Reuters) - Data from a pivotal trial of Amgen Inc's experimental melanoma therapy shows that it improved survival by 21 percent for patients with advanced forms of the deadly skin cancer compared with a standard white blood cell-boosting drug. Final survival results are not expected until later this year, but Wall Street has been awaiting the interim trial details to help assess the drug's commercial potential within a new market of promising melanoma treatments. ... Full Story | Top |
| Merck KGaA's Erbitux beats Avastin in bowel cancer trial Saturday, Jun 01, 2013 04:31 AM PDT FRANKFURT (Reuters) - Merck KGaA's cancer drug Erbitux was shown to be more effective at prolonging the lives of bowel cancer patients than Roche's Avastin, Merck said. In a drug trial, the two drugs were each given in combination with Folfiri chemotherapy to patients whose colorectal cancer had started spreading to other organs. The results showed the Erbitux group survived on average nearly four months longer than the Avastin group. The trial was conducted by an independent research collaborative of the German Association of Medical Oncology (AIO) and sponsored by Germany's Merck. ... Full Story | Top |
|
No comments:
Post a Comment